Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Pere Soler-Palacín is active.

Publication


Featured researches published by Pere Soler-Palacín.


The Journal of Allergy and Clinical Immunology | 2014

Clinical picture and treatment of 2212 patients with common variable immunodeficiency

Benjamin Gathmann; Nizar Mahlaoui; Laurence Gérard; Eric Oksenhendler; Klaus Warnatz; Ilka Schulze; Gerhard Kindle; Taco W. Kuijpers; Rachel T. van Beem; David Guzman; Sarita Workman; Pere Soler-Palacín; Javier de Gracia; Torsten Witte; Reinhold Schmidt; Jiri Litzman; Eva Hlavackova; Vojtech Thon; Michael Borte; Stephan Borte; Dinakantha S. Kumararatne; C. Feighery; Hilary J. Longhurst; Matthew R. Helbert; Anna Szaflarska; Anna Sediva; Bernd H. Belohradsky; Alison Jones; Ulrich Baumann; Isabelle Meyts

BACKGROUND Common variable immunodeficiency (CVID) is an antibody deficiency with an equal sex distribution and a high variability in clinical presentation. The main features include respiratory tract infections and their associated complications, enteropathy, autoimmunity, and lymphoproliferative disorders. OBJECTIVE This study analyzes the clinical presentation, association between clinical features, and differences and effects of immunoglobulin treatment in Europe. METHODS Data on 2212 patients with CVID from 28 medical centers contributing to the European Society for Immunodeficiencies Database were analyzed retrospectively. RESULTS Early disease onset (<10 years) was very frequent in our cohort (33.7%), especially in male subjects (39.8%). Male subjects with early-onset CVID were more prone to pneumonia and less prone to other complications suggesting a distinct disease entity. The diagnostic delay of CVID ranges between 4 and 5 years in many countries and is particularly high in subjects with early-onset CVID. Enteropathy, autoimmunity, granulomas, and splenomegaly formed a set of interrelated features, whereas bronchiectasis was not associated with any other clinical feature. Patient survival in this cohort was associated with age at onset and age at diagnosis only. There were different treatment strategies in Europe, with considerable differences in immunoglobulin dosing, ranging from 130 up to 750 mg/kg/mo. Patients with very low trough levels of less than 4 g/L had poor clinical outcomes, whereas higher trough levels were associated with a reduced frequency of serious bacterial infections. CONCLUSION Patients with CVID are being managed differently throughout Europe, affecting various outcome measures. Clinically, CVID is a truly variable antibody deficiency syndrome.


Haematologica | 2015

The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis

Sebastian Fn Bode; Sandra Ammann; Waleed Al-Herz; Mihaela Bataneant; Christopher C. Dvorak; Stephan Gehring; Andrew R. Gennery; Kimberly Gilmour; Luis Ignacio Gonzalez-Granado; Ute Groß-Wieltsch; Marianne Ifversen; Jenny Lingman-Framme; Susanne Matthes-Martin; Rolf M. Mesters; Isabelle Meyts; Joris M. van Montfrans; Jana Pachlopnik Schmid; Sung-Yun Pai; Pere Soler-Palacín; Uta Schuermann; Volker Schuster; Markus G. Seidel; Carsten Speckmann; Polina Stepensky; Karl-Walter Sykora; Bianca Tesi; Thomas Vraetz; Catherine Waruiru; Yenan T. Bryceson; Despina Moshous

Hemophagocytic lymphohistiocytosis is a hyperinflammatory syndrome defined by clinical and laboratory criteria. Current criteria were created to identify patients with familial hemophagocytic lmyphohistiocytosis in immediate need of immunosuppressive therapy. However, these criteria also identify patients with infection-associated hemophagocytic inflammatory states lacking genetic defects typically predisposing to hemophagocytic lymphohistiocytosis. These patients include those with primary immunodeficiencies, in whom the pathogenesis of the inflammatory syndrome may be distinctive and aggressive immunosuppression is contraindicated. To better characterize hemophagocytic inflammation associated with immunodeficiencies, we combined an international survey with a literature search and identified 63 patients with primary immunodeficiencies other than cytotoxicity defects or X-linked lymphoproliferative disorders, presenting with conditions fulfilling current criteria for hemophagocytic lymphohistiocytosis. Twelve patients had severe combined immunodeficiency with <100/μL T cells, 18 had partial T-cell deficiencies; episodes of hemophagocytic lymphohistiocytosis were mostly associated with viral infections. Twenty-two patients had chronic granulomatous disease with hemophagocytic episodes mainly associated with bacterial infections. Compared to patients with cytotoxicity defects, patients with T-cell deficiencies had lower levels of soluble CD25 and higher ferritin concentrations. Other criteria for hemophagocytoc lymphohistiocytosis were not discriminative. Thus: (i) a hemophagocytic inflammatory syndrome fulfilling criteria for hemophagocytic lymphohistiocytosis can be the initial manifestation of primary immunodeficiencies; (ii) this syndrome can develop despite severe deficiency of T and NK cells, implying that the pathophysiology is distinct and not appropriately described as “lympho”-histiocytosis in these patients; and (iii) current criteria for hemophagocytoc lymphohistiocytosis are insufficient to differentiate hemophagocytic inflammatory syndromes with different pathogeneses. This is important because of implications for therapy, in particular for protocols targeting T cells.


The Journal of Allergy and Clinical Immunology | 2015

IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis

Safia Hussain; Dorottya M. Berki; Siew-Eng Choon; A. David Burden; Michael H. Allen; Juan I. Aróstegui; Antonio Chaves; Michael Duckworth; Alan D. Irvine; Maja Mockenhaupt; Alexander A. Navarini; M.M.B. Seyger; Pere Soler-Palacín; Christa Prins; Laurence Valeyrie-Allanore; M. Asuncion Vicente; Richard C. Trembath; Catherine Smith; Jonathan Barker; Francesca Capon

Safia Hussain, BSc, Dorottya M Berki, BSc, Siew-Eng Choon, MRCP, A David Burden, MD, FRCP, Michael H Allen, PhD, Juan I Arostegui, MD, PhD, Antonio Chaves, MD, Michael Duckworth, Alan D Irvine, MD, Maja Mockenhaupt, MD, PhD, Alexander A Navarini, MD, PhD, Marieke MB Seyger, MD, PhD, Pere Soler-Palacin, MD, PhD, Christa Prins, MD, Laurence Valeyrie-Allanore, MD, M Asuncion Vicente, MD, Richard C Trembath, FMedSci, Catherine H Smith, MD, FRCP, Jonathan N Barker, MD, FRCP,* Francesca Capon, PhD,*


Pediatric Allergy and Immunology | 2009

Common variable immunodeficiency: 20-yr experience at a single centre.

Ma Pilar Llobet; Pere Soler-Palacín; Drahomíra Detková; Manuel Hernandez; Isabel Caragol; Teresa Espanol

Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency. It can present at any age in patients with a history of recurrent bacterial infections, with or without a family history of other primary immunodeficiencies (PID), and shows a wide range of clinical manifestations and immunological data. Diagnosis is based on low IgG, IgM and/or IgA levels. Delayed diagnosis and therapy can lead to bronchiectasis and malabsorption. The aim of this study was to describe a paediatric population diagnosed of CVID and its evolution in the population. Memory B‐cell (MB) classification carried out in these patients was correlated with clinical manifestations and outcome. Clinical and immunological data of 22 CVID children under 18 yr treated at our centre between 1985 and 2005 are presented. Immunological studies included those for diagnosis and MB quantification. Differences in form of presentation, familial incidence and MB classification were reviewed. A statistical descriptive analysis was made. Infections were the commonest manifestation, affecting mainly respiratory (19/22) and gastrointestinal (10/22) tracts. Bronchiectasis was present in seven cases, and detected prior to CVID diagnosis in five. Replacement therapy led to a significant reduction in the number of infections. Severe complications appeared mostly in patients without MB. Patients of the same family share the same MB group. Family members had also been diagnosed of CVID in seven cases. Early diagnosis and therapy are essential to improve outcome in these patients. MB studies are useful in children to orient prognosis and further genetic studies.


AIDS | 2011

Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens

Pere Soler-Palacín; Susana Melendo; Antoni Noguera-Julian; Clàudia Fortuny; María Luisa Navarro; María José Mellado; Lourdes Garcia; Sonia Uriona; Andrea Martín-Nalda; Concepció Figueras

Aim:To describe the impact of tenofovir disoproxil fumarate (TDF) use on renal function in HIV-infected pediatric patients. Design:It is a prospective, multicenter study. The setting consisted of five third-level pediatric hospitals in Spain. The study was conducted on patients aged 18 years and younger who had received TDF for at least 6 months. The intervention was based on the study of renal function parameters by urine and serum analyses. The main outcome measures were renal function results following at least 6 months of TDF therapy. Results:Forty patients were included (32 were white and 26 were diagnosed with AIDS). Median (range) duration of TDF treatment was 77 months (16–143). There were no significant changes in the estimated creatinine clearance. Urine osmolality was abnormal in eight of 37 patients, a decrease in tubular phosphate absorption was documented in 28 of 38 patients, and 33 of 37 patients had proteinuria. A statistically significant decrease in serum phosphate and potassium concentrations was observed during treatment (P = 0.005 and P = 0.003, respectively), as well as a significant relationship between final phosphate concentration and tubular phosphate absorption (P = 0.010). A negative correlation was found between phosphate concentration and time on TDF. Conclusions:TDF use showed a significant association with renal tubular dysfunction in HIV-infected pediatric patients. Periodic assessment of tubular function may be advisable in the follow-up of this population.


BMC Infectious Diseases | 2013

A new tool for the paediatric HIV research: general data from the Cohort of the Spanish Paediatric HIV Network (CoRISpe)

Mª Isabel de José; Santiago Jiménez de Ory; María Espiau; Clàudia Fortuny; Ma Luisa Navarro; Pere Soler-Palacín; Ma Ángeles Muñoz-Fernández

There are approximately from 1,100 to 1,200 HIV-infected children in a follow-up in Spain. In 2008 an open, multicentral, retrospective and prospective Cohort of the Spanish Paediatric HIV Network (CoRISpe) was founded. The CoRISpe is divided into the node 1 and node 2 representing geographically almost the whole territory of Spain. Since 2008 seventy-five hospitals have been participating in the CoRISpe. All the retrospective data of the HIV-infected children have been kept in the CoRISpe since 1995 and prospective data since 2008. In this article we are going to present the notion of CoRISpe, its role, the structure, how the CoRISpe works and the process how a child is transferred from Paediatric to Adults Units.The main objective of the CoRISpe is to contribute to furthering scientific knowledge on paediatric HIV infection by providing demographic, sociopsychological, clinical and laboratory data from HIV-infected paediatric patients. Its aim is to enable high-quality research studies on HIV-infected children.


Journal of Investigative Dermatology | 2016

AP1S3 Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 Production

Satveer K. Mahil; Sophie Twelves; Katalin Farkas; Niovi Setta-Kaffetzi; A. David Burden; Joanna E. Gach; Alan D. Irvine; László Képíró; Maja Mockenhaupt; Hazel H. Oon; Jason Pinner; Annamari Ranki; M.M.B. Seyger; Pere Soler-Palacín; Eoin R. Storan; Eugene S. Tan; Laurence Valeyrie-Allanore; Helen S. Young; Richard C. Trembath; Siew Eng Choon; Márta Széll; Z. Bata-Csörgö; Catherine Smith; Paola Di Meglio; Jonathan Barker; Francesca Capon

Prominent skin involvement is a defining characteristic of autoinflammatory disorders caused by abnormal IL-1 signaling. However, the pathways and cell types that drive cutaneous autoinflammatory features remain poorly understood. We sought to address this issue by investigating the pathogenesis of pustular psoriasis, a model of autoinflammatory disorders with predominant cutaneous manifestations. We specifically characterized the impact of mutations affecting AP1S3, a disease gene previously identified by our group and validated here in a newly ascertained patient resource. We first showed that AP1S3 expression is distinctively elevated in keratinocytes. Because AP1S3 encodes a protein implicated in autophagosome formation, we next investigated the effects of gene silencing on this pathway. We found that AP1S3 knockout disrupts keratinocyte autophagy, causing abnormal accumulation of p62, an adaptor protein mediating NF-κB activation. We showed that as a consequence, AP1S3-deficient cells up-regulate IL-1 signaling and overexpress IL-36α, a cytokine that is emerging as an important mediator of skin inflammation. These abnormal immune profiles were recapitulated by pharmacological inhibition of autophagy and verified in patient keratinocytes, where they were reversed by IL-36 blockade. These findings show that keratinocytes play a key role in skin autoinflammation and identify autophagy modulation of IL-36 signaling as a therapeutic target.


Blood | 2009

Role of TNFRSF13B variants in patients with common variable immunodeficiency.

Natalia Martínez-Pomar; Drahomíra Detková; Juan I. Aróstegui; Antonio Alvarez; Pere Soler-Palacín; Antonio Vidaller; Teresa Espanol; Almudena Sampalo; Javier de Gracia; Manuel Hernandez; Jordi Yagüe; Nuria Matamoros

To the editor: Sequence variants in TNFRSF13B gene, encoding the transmembrane activator and CAML interactor (TACI) protein, have been associated with common variable immunodeficiency (CVID) and IgA deficiency.[1][1][⇓][2]–[3][3] However, its detection among healthy persons and the absence of a


Pediatric Allergy and Immunology | 2016

Prospective neonatal screening for severe T‐ and B‐lymphocyte deficiencies in Seville

Beatriz de Felipe; Peter Olbrich; José Manuel Lucenas; Carmen Delgado-Pecellin; Antonio Pavon-Delgado; Josefina Marquez; Carmen Salamanca; Pere Soler-Palacín; Luis Ignacio Gonzalez-Granado; Laura Ferreras Antolin; Stephan Borte; Olaf Neth

Early diagnosis of primary immunodeficiency such as severe combined immunodeficiency (SCID) and X‐linked agammaglobulinemia (XLA) improves outcome of affected children. T‐cell‐receptor‐excision circles (TRECs) and kappa‐deleting‐recombination‐excision circles (KRECs) determination from dried blood spots (DBS) identify neonates with severe T‐ and/or B‐lymphopenia. No prospective data exist of the impact of gestational age (GA) and birth weight (BW) on TRECs and KRECs values.


Pediatric Infectious Disease Journal | 2009

Visceral leishmaniasis associated hemophagocytic syndrome in patients with chronic granulomatous disease.

Andrea Martín; Laura Marques; Pere Soler-Palacín; Isabel Caragol; Manuel Hernandez; Concepción Figueras; Teresa Espanol

Visceral leishmaniasis is a severe form of infection caused by a parasite endemic along the Mediterranean coast. Complications such as infection-associated hemophagocytic syndrome can occur despite correct therapy. We report visceral leishmaniasis-associated infection-associated hemophagocytic syndrome in 3 patients with chronic granulomatous disease.

Collaboration


Dive into the Pere Soler-Palacín's collaboration.

Top Co-Authors

Avatar

Andrea Martín-Nalda

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Concepció Figueras

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Aurora Fernández-Polo

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Marina Garcia-Prat

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Clara Franco-Jarava

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Laia Alsina

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Mónica Martínez-Gallo

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Roger Colobran

Autonomous University of Barcelona

View shared research outputs
Researchain Logo
Decentralizing Knowledge